Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
| ▸ | CPA1 | P15085 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | REN | P00797 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6317701 | 1.00 | CTSS (0.46) | CTSSCTSKMMP13PPARGPPARA | |
| SCHEMBL1401163 | 1.00 | CTSS (0.46) | CTSSCTSKMMP13PPARGPPARA | |
| SCHEMBL30884900 | 0.91 | CTSS (0.43) | CTSSCTSKPPARGPPARACPA1 | |
| SCHEMBL25173080 | 0.88 | PPARG (0.40) | MMP13PPARGPPARAITGB3ITGA2B | |
| SCHEMBL4778626 | 0.88 | CTSS (0.44) | CTSSCTSKMMP13ITGB3ITGA2B | |
| SCHEMBL8766144 | 0.88 | CTSS (0.44) | CTSSCTSKMMP13ITGB3ITGA2B | |
| SCHEMBL6661008 | 0.88 | CTSS (0.44) | CTSSCTSKMMP13ITGB3ITGA2B | |
| SCHEMBL2476924 | 0.87 | MMP13 (0.46) | CTSSCTSKMMP13ITGB3ITGA2B | |
| SCHEMBL1401042 | 0.87 | MMP13 (0.46) | CTSSCTSKMMP13ITGB3ITGA2B | |
| SCHEMBL65502 | 0.87 | MMP13 (0.46) | CTSSCTSKMMP13ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6559140-B2 | Cyclic and bicyclic diamino histamine-3 receptor antagonists | ABBOTT LABORATORIES | 2003-05-06 | — | — | US | disclosed |
| US-20010049367-A1 | Cyclic and bicyclic diamino histamine-3 receptor antagonists | ABBVIE INC. | 2001-12-06 | — | — | US | disclosed |
| WO-2001066534-A2 | CYCLIC AND BICYCLIC DIAMINO HISTAMINE-3 RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 2001-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049367-A1 | Cyclic and bicyclic diamino histamine-3 receptor antagonists | HRH4, HRH2, HRH3 | CTSS 2140/4885CTSK 1606/4885MMP13 2765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.